Like other vaccine candidates, for example the Oxford vaccine which sees an Italian participation, Ad5-nCov is made up of a viral vector (adenovirus 5) which transports some Sars-Cov-2 genes into the cells, provoking an immune reaction.
Among the most advanced projects in terms of time, the CanSino Bio vaccine in May, at the end of phase 1 of the trial, had demonstrated that it was safe and had been able to access phase 2, showing that it was able to produce a strong reaction immune by the body.
Hence the decision of China (and also of Canada, reports the Reuters agency ) to approve it for limited use . In the press note of the CanSino Bio company, in fact, it is specified that the approval arrived on June 25 and that it is valid for one year as a “specially needed drug”.
“Ad5-nCoV is currently limited to military use only and its use cannot be extended for a larger vaccination campaign without the approval of the logistics support department [of the Central Military Commission] . “
It is not known whether the vaccine will be compulsorily administered to soldiers or on a voluntary basis. As Reuters reports, the Chinese pharmaceutical giant has refused to respond as a “trade secret” .
The other candidates
In early June, China offered employees of state-owned companies travelling overseas the opportunity to access two other Sars-Cov-2 vaccine candidates.
At the same time, the Chinese Academy of Military Sciences has received approval to test another experimental vaccine, called ArCov, which is based on RNA technology – the same approach used by vaccine candidates of Moderna Inc (USA) and CureVac (Germany). Indeed, ArCov has given promising results in studies on non-human primates.
Recall, however, that of the hundreds of Covid-19 vaccine projects in development around the world, about twenty are being tested on humans. However, no one is yet approved for commercial use .